Her2-Positive Breast Cancer Patients Benefit From Herceptin Plus Chemotherapy Treatment

Her2-Positive Breast Cancer Patients Benefit From Herceptin Plus Chemotherapy Treatment
shutterstock_171523535Results from two randomized studies titled “Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831 and published in the Journal of Clinical Oncology, showed that combining trastuzumab (Herceptin) with chemotherapy can significantly improve the overall and disease-free survival of women with early stage HER2-positive breast cancer. Around 15 to 20% of all invasive breast cancers are diagnosed as HER2-positive. Before Herceptin (a monoclonal antibody targeting the HER2/neu receptor) was developed, women diagnosed with HER2-negative breast cancer had a better prognosis than those with early stage breast cancer who showed faster relapse, higher incidence of metastasis, and shorter survival. “This long follow-up of patients shows that we have really altered the natural history of this disease. Herceptin works — and it works for a long period of time. The drug has impacted the lives of many women in the U.S. a
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.